Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammaplex 10% versus Gammaplex 5% bioequivalence study in primary immunodeficiency diseases
2013-002290-21Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Oct 2013
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin in Immunogenetic disorder (3 arms), sponsored by Bio Products Laboratory. Primary endpoint: Bioequivalence of AUC0-28. Started Oct 2013; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2013-002290-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002290-21.